A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) (LIN-MD-62)
This study is currently recruiting participants.
Verified July 2017 by Forest Laboratories
First Posted: September 24, 2015
Last Update Posted: July 21, 2017
Ironwood Pharmaceuticals, Inc.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||March 31, 2018|
|Estimated Primary Completion Date:||March 31, 2018 (Final data collection date for primary outcome measure)|